@misc{hytoenen_activation_of_2016, 
author={Hytoenen, J., Leppaenen, O., Braesen, J.H., Schunck, W.-H., Mueller, D., Jung, F., Mrowietz, C., Jastroch, M., Bergwelt-Baildon, M.V., Kappert, K., Heuser, A., Drenckhahn, J.-D., Pieske, B., Thierfelder, L., Ylae-Herttuala, S., Blaschke, F.},
title={Activation of Peroxisome Proliferator–Activated Receptor-Delta as Novel Therapeutic Strategy to Prevent In-Stent Restenosis and Stent Thrombosis},
year={2016},
howpublished = {journal article},
doi = {https://doi.org/10.1161/ATVBAHA.115.306962},
abstract = {Conclusions—In contrast to commonly used drugs for stent coating, PPARδ ligands not only inhibit inflammatory response and proliferation of VSMCs but also prevent thrombocyte activation and support vessel re-endothelialization. Thus, pharmacological PPARδ activation could be a promising novel strategy to improve drug-eluting coronary stents outcomes.},
note = {Online available at: \url{https://doi.org/10.1161/ATVBAHA.115.306962} (DOI). Hytoenen, J.; Leppaenen, O.; Braesen, J.; Schunck, W.; Mueller, D.; Jung, F.; Mrowietz, C.; Jastroch, M.; Bergwelt-Baildon, M.; Kappert, K.; Heuser, A.; Drenckhahn, J.; Pieske, B.; Thierfelder, L.; Ylae-Herttuala, S.; Blaschke, F.: Activation of Peroxisome Proliferator–Activated Receptor-Delta as Novel Therapeutic Strategy to Prevent In-Stent Restenosis and Stent Thrombosis. Arteriosclerosis, Thrombosis, and Vascular Biology : ATVB. 2016. vol. 36, no. 8, 1534-1548. DOI: 10.1161/ATVBAHA.115.306962}}